Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 5891

AnaptysBio reports Phase 2 fail in ulcerative colitis; Lyell's CAR-T licensing deal

$
0
0
Plus, news about Tenaya, AtaiBeckley, Galecto, Damora, A2 Biotherapeutics, AstraZeneca and Evommune: 📉 AnaptysBio's lead drug fails ulcerative colitis study: The company said the T cell depleter ...

Viewing all articles
Browse latest Browse all 5891

Trending Articles